Open AccessSafety of Certolizumab Pegol in Chronic Plaque Psoriasis: Cumulative Data Over 48 Weeks' Exposure from Phase 3, Multicenter, Randomized, Placebo-Controlled Studies
Author(s) -
Andrew Blauvelt,
Bruce Strober,
Richard Langley,
Daniel Burge,
Lisa Pisenti,
Mohamed Yassine,
Sarah Kavanagh,
Catherine Arendt,
Robert Rolleri,
Kristian Reich
Publication year - 2018
Publication title -
skin the journal of cutaneous medicine
Language(s) - English
Resource type - Journals
ISSN - 2574-1624
DOI - 10.25251/skin.2.supp.16
Subject(s) - certolizumab pegol , placebo , medicine , plaque psoriasis , psoriasis , randomized controlled trial , dermatology , adalimumab , pathology , alternative medicine , tumor necrosis factor alpha
not available. Disclosures: Study sponsored by UCB Pharma. Copyright 2018 SKIN
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom